AngioSoma (OTCQB:SOAN) said today that it landed a joint venture with La Jolla Capital to help fund and manage phase III trials studying its flagship product, Liprostin.
The Montgomery, Texas-based company has completed 1 phase I and 3 phase II clinical trials evaluating its lead pharmaceutical candidate. Liprostin is a liposomal encapsulated prostaglandin, developed to treat peripheral artery disease.
“If Liprostin treated 10% of the 12 million untreated peripheral artery disease patients in the U.S. as reported by the American Heart Association, this could produce a gross income of $600 million if we assumed the company yields $500 per patient,” prez & CEO Alexanderia Blankenship said in prepared remarks.
“AngioSoma, Inc.’s Liprostin is in a rather unique position as it has completed Phase I and Phase II clinical trials,” La Jolla Capital Partners prez C. Piazza said. “This puts AngioSoma, Inc. in a position that most small companies never reach – at the brink of Phase III FDA trials with a possibly huge licensing opportunity.”
The post AngioSoma taps La Jolla Capital for Liprostin JV appeared first on MassDevice.
from MassDevice http://ift.tt/2duIfGu
Cap comentari:
Publica un comentari a l'entrada